Bethany Andrews Rhoten on Body Image Issues Among Patients With Head and Neck Cancer

The immunotherapy Opvido and reirradiation resulted in a one-year progression-free survival rate of 61.7% among certain patients with head and neck cancer.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

Having social media platforms to share breast cancer experiences changes the narrative for others who may empathize, a survivor and advocate said.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Retevmo was approved for childhood metastatic medullary thyroid, thyroid and solid tumors with RET mutations or gene fusions.

When compared with unvaccinated patients, HPV vaccines were associated with lower rates of HPV-related cancer for people younger than 40.